Besprin Mechanism of Action

Pharmacology: Pharmacodynamics: Aspirin is a nonsteroidal anti-inflammatory agent with analgesic, antipyretic and anti-inflammatory properties which inhibits platelet aggregation by blocking thromboxane A2 synthesis. The thromboxane A2 is an important lipid responsible for platelet aggregation, which can lead to blood clotting and future risk of heart attack or stroke.
Pharmacokinetics: Aspirin and other salicylates are absorbed rapidly from the gastrointestinal tract but absorption following rectal administration is less reliable than after oral administration. Aspirin and other salicylates can also be absorbed through the skin.
Following oral administration, absorption of non-ionized aspirin occurs in the stomach and intestine. Some aspirin is hydrolysed to salicylate in the gut wall. After absorption, aspirin is rapidly converted to salicylate but during the first 20 minutes following oral administration, aspirin is the predominant form of the drug in the plasma.
Aspirin is 80% to 90% bound to plasma proteins and is widely distributed; its volume of distribution is reported to be 170 mL per kg body-weight in adults. As plasma drug concentration increases, the binding sites on the proteins become saturated and the volume of distribution increases. Both aspirin and salicylate have pharmacological activity although only aspirin has an anti-platelet effect. Salicylate is extensively bound to plasma proteins and is rapidly distributed to all body parts. Salicylates appears in breast milk and crosses the placenta.